Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin. Analyses of dermatological irAEs have identified an association with improved overall survival (OS) following anti-PD-(L)1 therapy, but the factors that contribute to this relationship are poorly understood. We collected germline whole-genome sequencing data from IMvigor211, a recent phase 3 randomized controlled trial comparing atezolizumab (anti-PD-L1) monotherapy to chemotherapy in bladder cancer. We found that high vitiligo, high psoriasis, and low atopic dermatitis polygenic risk scores (PRSs) were associated with longer OS under anti-PD-L1 monotherapy as compared to chemotherapy, reflecting the Th17 polarization of these diseases. PRSs were not correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures. Shared genetic factors impact risk for dermatological autoimmunity and anti-PD-L1 monotherapy in bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a polygenic risk score (PRS) designed to calculate risk for vitiligo, psoriasis, and atopic dermatitis was predictive of response to ICBs in bladder cancer”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Khan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“The PD-1 immune checkpoint acts to restrict T cell responses and contributes to the regulation of immune self-tolerance (4, 5).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“The tumor microenvironment (TME) consists of a complex mixture of immune cells, stromal, and tumor cells (22).”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“Taken together, these observations support the notion that an immune set point, at least in part determined by germline genetic variation, may influence the efficacy of immune checkpoint blockade (1).”
BackgroundSelf-citationImmune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · cited 1×
“Consistent with this role, patients develop immune-related adverse events (irAEs) that are thought to be autoimmune in origin, but the link is poorly understood (6, 7).”
BackgroundxCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 1×
“Using pretreatment, bulk tumor gene expression for n = 398 individuals with both RNA-seq and germline genetic data, we generated immune and stromal celltype enrichment scores, and, to limit the multiple testing burden, we associated them with PRSs that had the strongest trial arm by risk score interaction for each der…”
MethodBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 2×
“We confirmed a similar distribution of irAE in IMvigor210 (N=429), a phase 2 single-arm trial for treatment of mUC(14, 15).”
BackgroundResultSelf-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · cited 1×
“We confirmed a similar distribution of irAE in IMvigor210 (N=429), a phase 2 single-arm trial for treatment of mUC(14, 15).”
ResultSelf-citationThe personal and clinical utility of polygenic risk scores
Torkamani, A., Wineinger, N. E., & Topol, E. J. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0018-x · Cited by 1,623
Power and predictive accuracy of polygenic risk scores
Dudbridge, F. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003348 · Cited by 1,509
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408 · cited 2×
“To examine the relationship between safety and efficacy of checkpoint blockade, we conducted an analysis of irAEs using data from safety evaluable patients (N=459) receiving atezolizumab in IMvigor211(13).”
MethodResultSelf-citationHuman Demographic History Impacts Genetic Risk Prediction across Diverse Populations
Martin, A. R., Gignoux, C. R., Walters, R. K., Wojcik, G. L., Neale, B. M., Gravel, S., Daly, M. J., Bustamante, C. D., & Kenny, E. E. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.03.004 · Cited by 1,391
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211 · cited 1×
“The PD-1 immune checkpoint acts to restrict T cell responses and contributes to the regulation of immune self-tolerance (4, 5).”
BackgroundSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“In mice, systemic immunity is required for successful tumor rejection by PD-1 checkpoint blockade, and substantial evidence supports the role for host factors in influencing systemic immunity (2, 3).”
BackgroundFreeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Brodin, P., & Davis, M. M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2016.125 · Cited by 730 · cited 1×
“In mice, systemic immunity is required for successful tumor rejection by PD-1 checkpoint blockade, and substantial evidence supports the role for host factors in influencing systemic immunity (2, 3).”
BackgroundHua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
the EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium (2015) · Nature Genetics · doi:10.1038/ng.3424 · Cited by 621
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1916 · Cited by 449
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · cited 1×
“Consistent with this role, patients develop immune-related adverse events (irAEs) that are thought to be autoimmune in origin, but the link is poorly understood (6, 7).”
BackgroundAtopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Guttman-Yassky, E., & Krueger, J. G. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.08.008 · Cited by 412 · cited 3×
“The GWAS p-value cutoffs at which we observed significant associations differed between OS and skin irAEs, as well as across diseases, reflecting the differing degrees of genetic sharing and statistical power of the GWASs underlying the PRSs (see Supplemental Discussion).”
BackgroundWeidinger, S., Willis-Owen, S. A. G., Kamatani, Y., Baurecht, H., Morar, N., Liang, L., Edser, P., Street, T., Rodriguez, E., O'Regan, G. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt317 · Cited by 219
Nakamura, Y., Tanaka, R., Asami, Y., Teramoto, Y., Imamura, T., Sato, S., Maruyama, H., Fujisawa, Y., Matsuya, T., Fujimoto, M., et al. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13520 · Cited by 218
Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes
Okada, Y., Han, B., Tsoi, L. C., Stuart, P. E., Ellinghaus, E., Tejasvi, T., Chandran, V., Pellett, F., Pollock, R., Bowcock, A. M., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.07.002 · Cited by 215
The role of IL-17 in vitiligo: A review
Singh, R. K., Lee, K. M., Vujkovic-Cvijin, I., Ucmak, D., Farahnik, B., Abrouk, M., Nakamura, M., Zhu, T. H., Bhutani, T., Wei, M., et al. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.004 · Cited by 145 · cited 3×
“The GWAS p-value cutoffs at which we observed significant associations differed between OS and skin irAEs, as well as across diseases, reflecting the differing degrees of genetic sharing and statistical power of the GWASs underlying the PRSs (see Supplemental Discussion).”
BackgroundMeta-Analysis of the Association between Vitiligo and Human Leukocyte Antigen-A
Li, Z., Ren, J., Niu, X., Xu, Q., Wang, X., Liu, Y., & Xiao, S. (2016) · BioMed Research International · doi:10.1155/2016/5412806 · Cited by 16
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
“Interestingly, research has revealed that a polygenic risk score (PRS) designed to assess the risk for conditions like vitiligo, psoriasis, and atopic dermatitis can serve as a predictor of response to ICBs, as demonstrated in bladder cancer cases [208].”
BackgroundPrognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Nishio, M., Mok, T. S. K., Reck, M., Finley, G. G., Kaul, M. D., Yu, W., Paranthaman, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7711 · Cited by 186
“Rash 20 (35) 26 (32) 32 (32) 29 (32) Pneumonitis 9 (16)b 11 (14) 12 (12)b 7 (8) Colitis 3 (5) 6 (7) 7 (7) 6 (7) Severe cutaneous reaction 3 (5) 4 (5) 4 (4) 3 (3) Pancreatitis 2 (3) 2 (3) 4 (4) 5 (5) Nephritis 0 0 5 (5) 6 (7) Diabetes 0 3 (4) 3 (3) 3 (3) Encephalitis 2 (3) 2 (3) 2 (2) 2 (2) Hypothyroidism 0 0 4 (4) 4 (…”
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 159
Metadata
- Authors
- Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., Chen-Harris, H., Bhangale, T., Mellman, I., Rosenberg, J., Powles, T., Hunkapiller, J., Chandler, G. S., & Albert, M. L.
- Affiliations
- Genentech (US)
- Genentech, South San Francisco, CA 94080;
- Memorial Sloan Kettering Cancer Center (US)
- Queen Mary University of London (GB)
- Corresponding author
- Khan, Zia
- Mellman, Ira
- Albert, Matthew L.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-05-19
- Volume
- 117
- Issue
- 22
- Pages
- 12288-12294
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7275757
- OpenAlex
- W3026699635
- Cited by
- 91
- References
- 27
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 12 · 2023: 19 · 2022: 22 · 2021: 16 · 2020: 3
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- polygenic risk score, skin autoimmunity, immune checkpoint blockade, bladder cancer, PD-L1 blockade, atezolizumab, vitiligo, psoriasis, atopic dermatitis, immune-related adverse events, Th17 polarization, overall survival, germline mutations
- MeSH terms
- Urinary Bladder Neoplasms, Humans, Skin, Cohort Studies, Autoimmunity, Multifactorial Inheritance, Th17 Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.